Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (250)	5/29/2001 12:28:44 PM
From: Jim Oravetz	Read Replies (1) of 370

clinicaltrials.gov VNP20009 in Treating Patients With Advanced Solid Tumors This study is currently recruiting patients. Sponsored by Vion Pharmaceuticals Purpose RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced solid tumors. Other: No artificial implant that cannot be removed (e.g., prosthetic hips or knees or other devices) No permanent central venous catheters No gallstones No active infection No documented Salmonella infection No tumor fever or fever of unknown origin or cause Daily maximum temperature no greater than 38.0 degrees Celsius HIV negative No documented immunodeficiency Hepatitis B surface antigen negative No other life threatening illness No history of allergic reaction or hypersensitivity to quinolone or cephalosporin antibiotics No commercial food handlers, day care workers, or health care workers No patients unable to avoid close personal contact with severely immunosuppressed individuals (e.g., other patients on myelosuppressive cancer chemotherapy) Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception 3-AP in Treating Patients With Advanced Cancer This study is currently recruiting patients. Sponsored by Vion Pharmaceuticals Purpose RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 3-AP in treating patients who have advanced cancer. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next